• Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, P. R. China;
LI Ning, Email: md.lining@whu.edu.cn; GENG Qing, Email: gengqingwhu@whu.edu.cn
Export PDF Favorites Scan Get Citation

Lung cancer is the malignant tumor with the highest incidence rate in men and the highest mortality rate in men and women in China, and the incidence and mortality rates are still increasing. Lung cancer screening is an important initiative for early detection of lung cancer and improvement of prognosis. The National Comprehensive Cancer Network (NCCN) updates the NCCN Clinical Practice Guidelines for Lung Cancer Screening annually, and the 2023 V2 edition was released in May 2023. The guidelines are based on the latest research advances and high-level evidence-based medical evidence to establish screening criteria for lung cancer, especially for non-small cell lung cancer, which is the most common and highly regarded type of lung cancer, and has received widespread attention from physicians worldwide. In this article, the latest version of the guideline will be interpreted based on China's national situation and Chinese lung cancer screening guidelines, with the aim of providing an updated reference for lung cancer screening in China.

Citation: LUO Guoqing, WANG Wenjie, LU Xiao, LI Ning, GENG Qing. Interpretation of the NCCN clinical practice guidelines in oncology for lung cancer screening (version 2.2023). Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023, 30(9): 1217-1223. doi: 10.7507/1007-4848.202306011 Copy

  • Previous Article

    第十四届宁夏国际心血管病论坛暨2023年宁夏心血管外科高峰论坛会议纪要
  • Next Article

    Selective mediastinal lymph node dissection: Precision surgery in the era of precision medicine